课件：肺癌内科治疗进展.pptx

后面内容直接删除就行资料可以编辑修改使用资料可以编辑修改使用主要经营：网络软件设计、图文设计制作、发布广告等公司秉着以优质的服务对待每一位客户，做到让客户满意！致力于数据挖掘，合同简历、论文写作、PPT设计、计划书、策划案、学习课件、各类模板等方方面面，打造全网一站式需求感谢您的观看和下载The user can demonstrate on a projector or computer, or print the presentation and make it into a film to be used in a wider field非小细胞肺癌内科治疗进展周彩存同济大学附属上海市肺科医院化疗进展早期术后辅助化疗：个体化？局部晚期 同步化放疗，AP未超越EP鳞癌：白蛋白紫杉醇普通紫杉醇;　ND优于DP非鳞癌 分子靶向治疗 贝伐单化疗优于化疗 培美优于健择 连续维持治疗改善总体生存免疫治疗辅助治疗的必要性辅助化疗是淋巴结阳性完全切除早期NSCLC的标准治疗在淋巴结阴性病人,仍存在争议顺铂为基础方案是标准卡铂为基础方案未得到批准,但经常使用证据最多的是NPECOG1505允许所有未批准的方案BRCA1水平和含铂药物化疗的相关性Yang Y et al.J Exp Clin Cancer Res,2013Customized BRCA1 Adjuvant Treatment in Stage II-II NSCLC (SCAT)CONTROLDocetaxel/Cis1..3ResectedNSCLC R0pN1 / pN2T1 BRCA1Gem/CisEXPERIMENTALT2 BRCA1Docetaxel/CisStatification factors:-Stage: N1 vs. N2-Age ≤65 vs 65 y-Histology: Non-SCC vs. SCC-Type of resection: Lobectomy vs PneumonectomyT3 BRCA1DocetaxelEudract: 2007-000067-15NCTgovlanned number of patients : 432 (amended)CT should be started before 8 weeks after surgeryPORT in N2 patientsSLIDES ARE THE PROPERTY OF THE AUTHOR.PERMISSION REQUIRED FOR REUSE.Presented By Mark Socinski at 2015 ASCO Annual MeetingCustomized BRCA1 Adjuvant Treatment in Stage II-II NSCLC (SCAT)CONTROLDocetaxel/Cis1..3ResectedNSCLC R0pN1 / pN2T1 BRCA1Gem/CisEXPERIMENTALT2 BRCA1Docetaxel/CisPrimary Endpoint: OS5 yr OS 45% → 65%T3 BRCA1DocetaxelEudract: 2007-000067-15NCTgovLIDES ARE THE PROPERTY OF THE AUTHOR.PERMISSION REQUIRED FOR REUSE.Presented By Mark Socinski at 2015 ASCO Annual Meeting实验组的OS1.00.80.6OS0.4HR低水平 vs 高水平：0.84中等水平 vs 高水平：0.95BRCA1低水平0.2BRCA1中等水平BRCA1高水平0.001020304050607080时间 (月)BRCA1高水平患者DFS和OSBRCA1高表达者未显示顺铂耐药。1.01.00.80.80.60.60.40.4DFSOS试验组试验组0.20.2对照组对照组HR=1.87 (0.83-4.19)HR=1.24 (0.59-2.59)0.00.00102030405060708001020304050607080时间 (月)时间 (月)Massuti B, et al. 2015 ASCO Abstract 7507.BRCA1低表达患者DFS和OSBRCA1低表达者多见于腺癌、非吸烟和女性患者。1.01.00.80.80.60.60.40.4DFSOS试验组试验组0.20.2对照组对照组HR=0.64 (0.38-1.09)HR=0.50 (0.28-0.88)P=0.0160.00.00102030405060708001020304050